Does tesamorelin 10 mg mean 10 mg per injection?

No. Tesamorelin 10 mg usually describes the total peptide mass in the whole vial, not the amount for one injection. The prescribed drug amount and the liquid volume used to measure it come from the provider's plan and the dispensing pharmacy's label. The front number alone is not enough to work either one out.

How many doses are in a 10 mg tesamorelin vial?

The vial number alone cannot answer that. Days of supply also depends on the prescribed amount, frequency, concentration, whether the vial permits repeated withdrawals, and its beyond-use date. The dispensing label should state the intended supply and measured amount. A brand example or another person's instructions should not be used to calculate a compounded vial.

Why does Egrifta WR contain 11.6 mg but list 1.28 mg?

They describe different things. The 11.6 mg figure is the total amount in one Egrifta WR vial, while 1.28 mg is the label's daily amount for that specific formulation. DailyMed says one prepared vial provides seven daily amounts. It is a useful example of why vial strength and one-use amount are not interchangeable.

Is a 20 mg tesamorelin vial stronger than a 10 mg vial?

It contains more total peptide mass if the labels otherwise describe the same ingredient, but that does not mean one injection is stronger. Per-use strength depends on the prescribed drug amount and the concentration after preparation. Those details may differ by formulation, so the pharmacy directions—not the larger front number—determine what the prescription means.

Is compounded tesamorelin the same as Egrifta WR?

No. FDA-approved tesamorelin products exist, but the compounded formulation offered here is not FDA-approved. Concentration, inactive ingredients, preparation, storage, and measured volume may differ. A licensed provider may still prescribe a compounded formulation when appropriate; that decision belongs to the patient and doctor, and the dispensing label governs the specific vial.

What if new tesamorelin directions differ from an old vial?

The current prescription and dispensing label control. A changed vial strength or concentration can make an old measured volume incorrect even when the syringe looks familiar. The medication should remain unused until the prescriber or dispensing pharmacy confirms which directions apply. That check is especially important after a refill, formulation change, or pharmacy change.

Tesamorelin 10 mg: What the Vial Number Means

Tesamorelin 10 mg on a vial usually means the whole vial contains 10 milligrams of tesamorelin. A milligram, shortened to mg, measures drug mass. That front number does not tell you the amount for one injection, the liquid volume to measure, or how many days the vial should last.

The same rule applies to a label that says 5 mg or 20 mg. The vial number describes the whole container. The prescription and pharmacy directions describe the portion prepared for one use.

Why tesamorelin 10 mg is not a dose

A dose is the amount prescribed for one administration. Vial size is the total amount packaged in the container. Those can be the same for a single-dose product, but they are not automatically the same.

Three different units often appear near each other:

Label information	What it means	What it does not tell you by itself
10 mg per vial	Total tesamorelin mass in the container	The prescribed amount for one injection
mg/mL	Concentration, or how much drug is in each milliliter of liquid	The amount a particular person was prescribed
mL or syringe units	Liquid volume	Drug mass unless the concentration is also known

This is why two vials can show the same total milligrams and still come with different measured volumes. The formulation—the product's exact recipe and strength—the added liquid, and the prescription all matter. A screenshot of somebody else's syringe is missing most of that information.

The words beside the number matter too. “Per vial” points to the container total. “Per mL” points to concentration. “Per dose” or the prescription directions point to one administration. A bare 10 mg number cannot connect those pieces on its own.

The current brand label makes the difference clear

As of September 9, 2026, the day this article was written, DailyMed's official Egrifta WR record showed an update date of July 29, 2026. It lists 11.6 mg in the vial, a labeled amount of 1.28 mg for each day, and seven days of medication from one prepared vial. In other words, even the brand's large front-of-vial number is not its one-use amount.

The label also says Egrifta WR and Egrifta SV are not substitutable. Their vial strengths, preparation steps, measured amounts, and storage rules differ. A number from one formulation cannot safely fill in a blank on another.

Through Promise, tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a licensed pharmacy prepares a medication for an individual prescription. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

Where the older 2 mg number came from

The 2 mg figure seen online is not invented. It came from an older tesamorelin formulation used in the major clinical studies, not from a rule for interpreting every vial.

A 2007 trial randomly assigned 412 adults with HIV and excess abdominal fat to the original formulation at 2 mg per day or placebo for 26 weeks (Falutz et al., New England Journal of Medicine, 2007). A 2010 analysis combined two large trials with 806 adults and again reported the original 2 mg daily study regimen (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010). These are study facts, not instructions for a 10 mg compounded vial.

The current Egrifta WR label says its 1.28 mg amount produces similar drug exposure to 2 mg of the original formulation. Drug exposure means how much medicine reaches the body over time. That difference is exactly why matching milligram numbers across formulations is unsafe. The prescriber makes the actual amount and monitoring decisions.

A tesamorelin-and-ipamorelin vial adds another layer: two compounds share one formulation in a fixed ratio, meaning their proportions stay linked as the measured volume changes. The pharmacy sets that ratio. Neither the single-compound brand label nor directions from a tesamorelin-only vial can be transferred to the blend.

How vial size relates to days of supply

A larger vial may hold more total peptide, but it does not promise a particular number of days. Days of supply depends on the prescribed amount, how often it is scheduled, whether the vial is meant for one or several withdrawals, and the beyond-use date. A beyond-use date is the pharmacy's deadline for using a compounded preparation.

The Egrifta WR label answers the question directly for that product: one prepared 11.6 mg vial provides seven daily amounts. A compounded 10 mg vial needs its own answer on the dispensing label. It should not be reverse-engineered from the Egrifta example or from the front number alone.

There can also be medication left in a vial when its permitted use window ends. That does not create an extra dose. The written discard instruction remains part of the prescription, even when the container does not look empty.

Why reconstitution math belongs to the pharmacy

Reconstitution means mixing freeze-dried medicine with a specified liquid. The process changes concentration and volume; it does not change how many milligrams were in the sealed vial. A 10 mg vial remains a 10 mg vial after mixing, but the amount in each milliliter depends on the exact liquid volume and formulation.

That is where online arithmetic becomes risky. A person can calculate the volume correctly for the wrong concentration and still measure the wrong amount. The prescriber sets the drug amount. The dispensing pharmacy specifies the preparation, translates the prescription into a measured volume, and prints directions for that exact product.

If a vial arrives already prepared as a liquid, there may be no mixing step at home at all. Formulations vary by pharmacy and prescription, so the directions in the package settle the question.

Keep amount, technique, and storage separate

Vial size answers one question: how much tesamorelin is in the whole container. It does not replace the three instructions that govern use.

The prescribed amount and schedule belong to the tesamorelin dosage guide.
The route, site, and handling steps belong to the tesamorelin injection guide.
Temperature, light, and discard timing belong to the peptide storage guide.

A usable pharmacy label connects those pieces. It identifies the patient and medication, states the concentration, gives the prescribed measured amount and frequency, and carries storage and beyond-use directions. The lot number identifies the production batch, while a pharmacy contact creates a clear path for questions.

What a recent FDA letter adds

As of September 9, 2026, the day this article was written, an FDA warning letter dated August 24, 2026 addressed an online seller's unapproved tesamorelin products, including a 10 mg listing. That letter was about one seller's products and marketing. It does not mean every vial with 10 mg on the front is the same product; it means the rest of the label and supply chain matter.

The useful dividing line is accountability. A grey-market vial sold without a prescription leaves the front number to do all the talking. A prescribed route ties the vial to a named patient, a licensed provider, a licensed U.S. pharmacy, a traceable production batch, and product-specific directions.

At Promise, a licensed provider reviews every request and decides whether tesamorelin is appropriate; not everyone qualifies. If the vial number, concentration, or directions do not match the current plan, the medication should remain unused until the prescriber or dispensing pharmacy resolves the mismatch.